Chimeric Therapeutics Limited (ASX:CHMO)

Market Cap	9.76M -33.3%
Revenue (ttm)	12.68M +70.1%
Net Income	-10.43M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,035,000
Average Volume	4,717,638
Open	0.0010
Previous Close	0.0010
Day's Range	0.0010 - 0.0010
52-Week Range	0.0010 - 0.0030
Beta	n/a
RSI	48.13
Earnings Date	n/a

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHMO